저온 플라즈마 시장 예측(-2031년) : 산업별, 용도별, 제도별, 지역별

The global cold plasma market is projected to reach USD 3.03 billion by 2031 from USD 2.15 billion in 2026, at a CAGR of 7.1 % during the forecast period.

The growing need for effective, low-temperature sterilization and surface modification of medical devices is driving the adoption of cold plasma technology. Cold plasma enables non-thermal treatment of heat-sensitive medical devices while reducing reliance on harsh chemicals and minimizing material damage.

Increasing demand for sterile medical equipment, infection control, and advanced surface treatment, particularly for catheters, implants, surgical instruments, and other polymer-based devices, is expected to support market growth. Furthermore, rising healthcare expenditure, stringent sterilization requirements, and advancements in plasma-based medical technologies are likely to drive further adoption of cold plasma solutions.

"Based on industry, the medical industry segment of the cold plasma market is expected to register the highest share during the forecast period."

The growing adoption of plasma-based solutions for wound healing, sterilization, disinfection, and surgical applications mainly drives the demand for cold plasma technology in the medical industry. The increasing prevalence of chronic wounds, rising demand for minimally invasive procedures, and growing emphasis on infection prevention are supporting the adoption of cold plasma systems across hospitals, clinics, and medical-device manufacturing facilities. Moreover, the focus on non-thermal sterilization, antimicrobial treatment, reduced chemical usage, patient safety, and environmentally friendly healthcare processes is encouraging the adoption of cold plasma technologies. Technological advancements in atmospheric-pressure plasma jets, plasma-based wound-care devices, and plasma sterilization systems are further expanding the scope of cold plasma applications, supporting the medical industry segment in registering the highest share during the forecast period.

"By application, the surface treatment & activation segment is expected to capture the highest CAGR of the cold plasma market."

Based on application, the surface treatment & activation segment is anticipated to register the highest CAGR during the forecast period. This growth can be attributed to the increasing use of cold plasma to enhance surface adhesion, wettability, printability, and bonding properties across polymer & plastics, textiles, electronics, and automotive applications.

The non-thermal, environmentally friendly nature of cold plasma, along with its ability to reduce reliance on chemical treatments, is driving its adoption across industries. Moreover, advancements in plasma technology, development of application-specific systems, and increasing demand for efficient and customizable surface treatment solutions are expected to further accelerate segment growth.

"By regime, the low-pressure cold plasma segment is expected to register the highest CAGR in the cold plasma market."

The low-pressure cold plasma segment is projected to record the highest CAGR, primarily due to its increasing use in high-precision manufacturing processes, particularly in semiconductor fabrication, electronics component processing, and specialized medical applications. The segment benefits from the ability to operate under controlled vacuum conditions, enabling precise plasma density, treatment uniformity, and repeatable process outcomes. Rising investments in advanced manufacturing facilities and the increasing integration of plasma-based processes into automated production lines are expected to further accelerate the adoption of low-pressure systems.

"Europe accounted for the largest share of the cold plasma market by region."

The global cold plasma market is segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. Europe is expected to account for a significant share of the global cold plasma market, supported by the increasing adoption of cold plasma technologies across medical, polymer & plastic, textile, and electronics industries, as well as the strong presence of key market players in the region.

The regional market is further supported by advanced manufacturing capabilities, stringent environmental regulations, growing demand for sustainable and chemical-free processing, and increasing investments in healthcare technologies. Moreover, the rising adoption of cold plasma for medical device sterilization, wound care, infection control, and industrial surface treatment, along with ongoing technological advancements and R&D activities, is expected to further drive market growth in Europe.

A breakdown of the primary participants referred to for this report is provided below:

• By Company Type: Tier 1 (45%), Tier 2 (25%), and Tier 3 (30%)
• By Designation: C-level Executives (35%), Directors (25%), and Other Designations (40%)
• By Region: North America (35%), Europe (25%), Asia Pacific (20%), Latin America (15%), and the Middle East & Africa (5%)

The major players operating in the cold plasma market are Apyx Medical (US), Nordson Corporation (US), Adtec Plasma Technology Co. Ltd. (Japan), P2i Ltd. (UK), Relyon Plasma GmbH (Germany), Henniker Plasma (UK), Enercon Industries Corporation (US), AcXys Plasma Technologies (France), Plasmatreat GmbH (Germany), Tantec A/S (Denmark), Europlasma NV (Belgium), Thierry Corp. (Germany), Surfx Technologies, LLC (US), SOFTAL Corona & Plasma GmbH (Germany), Coating Plasma Innovation (France), Ferrarini & Benelli (Italy), Neoplas GmbH (Germany), Terraplasma GmbH (Germany), Molecular Plasma Group SA (Germany), and CINOGY Technologies GmbH (Germany).

Research Coverage

This report studies the cold plasma market by industry, application, regime, and region. The report also examines factors such as drivers, restraints, opportunities, and challenges affecting market growth and provides details on the competitive landscape among market leaders. Furthermore, the report analyzes micromarkets by their individual growth trends and forecasts revenue for market segments across five major regions (and the countries within these regions).

Reasons to Buy the Report

The report will enable established firms, as well as entrants/smaller firms, to gauge the pulse of the market, which, in turn, will help them garner a larger market share. Firms purchasing the report could use one or a combination of the strategies mentioned below to strengthen their market presence.

This report provides insights on the following pointers:

• Analysis of key drivers (increased benefits and wider application, rising use in wound healing, growing applications in cancer and infectious disease, technological advancements, and rising demand for non-thermal sterilization and surface treatment), restraints (high capital investments and limited plasma penetration and non-uniform treatment), opportunities (sustainable and chemical-reduced processing and emerging countries offering opportunities), and challenges (limited commercialization and awareness and management of reactive species and process conditions)
• Product Enhancement/Innovation: Comprehensive details about new product launches and anticipated trends in the global cold plasma market.
• Product Development/Innovation: Detailed insights on upcoming trends, research & development activities, and new product launches in the global cold plasma market
• Market Development: Comprehensive information on the lucrative emerging markets by industry, application, and regime.
• Market Diversification: Exhaustive information about new products and services or product and service enhancements, growing geographies, recent developments, and investments in the global cold plasma market.
• Competitive Assessment: Thorough evaluation of the market shares, growth plans, offerings of products and services, and capacities of the major competitors in the global cold plasma market.

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 STUDY SCOPE
  • 1.3.1 MARKETS COVERED & REGIONAL SEGMENTATION
  • 1.3.2 INCLUSIONS & EXCLUSIONS
  • 1.3.3 YEARS CONSIDERED
  • 1.3.4 CURRENCY CONSIDERED
• 1.4 STAKEHOLDERS
• 1.5 SUMMARY OF CHANGES

2 EXECUTIVE SUMMARY

• 2.1 MARKET HIGHLIGHTS AND KEY INSIGHTS
• 2.2 KEY MARKET PARTICIPANTS: MAPPING OF STRATEGIC DEVELOPMENTS
• 2.3 DISRUPTIVE TRENDS IN COLD PLASMA MARKET
• 2.4 HIGH-GROWTH SEGMENTS
• 2.5 REGIONAL SNAPSHOT: MARKET SIZE, GROWTH RATE, AND FORECAST

3 PREMIUM INSIGHTS

• 3.1 COLD PLASMA MARKET OVERVIEW
• 3.2 ASIA PACIFIC: COLD PLASMA MARKET, BY COUNTRY AND END USER
• 3.3 GEOGRAPHIC SNAPSHOT OF COLD PLASMA MARKET

4 MARKET OVERVIEW

• 4.1 INTRODUCTION
• 4.2 MARKET DYNAMICS
  • 4.2.1 DRIVERS
    • 4.2.1.1 Growing preference for low-temperature and chemical-reduced processing to drive cold plasma adoption
    • 4.2.1.2 Rising use of cold plasma in wound healing
    • 4.2.1.3 Emerging applications in oncology and infectious diseases
    • 4.2.1.4 Technological advancements and product innovation
    • 4.2.1.5 Rising demand for non-thermal sterilization and surface treatment for medical devices
  • 4.2.2 RESTRAINTS
    • 4.2.2.1 High initial investments
    • 4.2.2.2 Limited plasma penetration and non-uniform treatment
  • 4.2.3 OPPORTUNITIES
    • 4.2.3.1 Growing focus on sustainable and chemical-reduced processing
    • 4.2.3.2 Favorable prospects in emerging economies
  • 4.2.4 CHALLENGES
    • 4.2.4.1 Limited commercialization and awareness
    • 4.2.4.2 Management of reactive species and process conditions during cold plasma operations
• 4.3 UNMET NEEDS AND WHITE SPACES
  • 4.3.1 UNMET NEEDS IN COLD PLASMA MARKET
  • 4.3.2 WHITE SPACE OPPORTUNITIES
• 4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES
  • 4.4.1 INTERCONNECTED MARKETS
  • 4.4.2 CROSS-SECTOR OPPORTUNITIES
• 4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS

5 INDUSTRY TRENDS

• 5.1 PORTER'S FIVE FORCES ANALYSIS
  • 5.1.1 THREAT OF NEW ENTRANTS
  • 5.1.2 THREAT OF SUBSTITUTES
  • 5.1.3 BARGAINING POWER OF BUYERS
  • 5.1.4 BARGAINING POWER OF SUPPLIERS
  • 5.1.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.2 MACROECONOMIC OUTLOOK
  • 5.2.1 INTRODUCTION
  • 5.2.2 GDP TRENDS & FORECAST
  • 5.2.3 TRENDS IN GLOBAL HEALTHCARE INDUSTRIES
  • 5.2.4 TRENDS IN GLOBAL MEDICAL DEVICE INDUSTRY
• 5.3 SUPPLY CHAIN ANALYSIS
• 5.4 VALUE CHAIN ANALYSIS
• 5.5 ECOSYSTEM ANALYSIS
• 5.6 PRICING ANALYSIS
  • 5.6.1 AVERAGE SELLING PRICE TREND, BY KEY PLAYER (2023-2025)
  • 5.6.2 AVERAGE SELLING PRICE TREND, BY REGIME (2023-2025)
  • 5.6.3 AVERAGE SELLING PRICE TREND, BY REGION (2023-2025)
• 5.7 TRADE ANALYSIS
  • 5.7.1 IMPORT SCENARIO (HS CODE 901890)
  • 5.7.2 EXPORT SCENARIO (HS CODE 901890)
• 5.8 KEY CONFERENCES & EVENTS, 2026-2027
• 5.9 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
• 5.10 INVESTMENT & FUNDING SCENARIO
• 5.11 CASE STUDY ANALYSIS
  • 5.11.1 CASE STUDY 1: COLD ATMOSPHERIC ARGON PLASMA FOR CHRONIC WOUND TREATMENT
  • 5.11.2 CASE STUDY 2: PLASMA SURFACE ACTIVATION OF PEEK FOR MEDICAL DEVICES
  • 5.11.3 CASE STUDY 3: PLASMA ACTIVATION FOR HIGH-QUALITY PAD PRINTING
• 5.12 IMPACT OF 2025 US TARIFFS-COLD PLASMA MARKET
  • 5.12.1 INTRODUCTION
  • 5.12.2 KEY TARIFF RATES
  • 5.12.3 PRICE IMPACT ANALYSIS
  • 5.12.4 IMPACT ON COUNTRIES/REGIONS
    • 5.12.4.1 Canada
    • 5.12.4.2 Asia Pacific
    • 5.12.4.3 Europe

6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS

• 6.1 KEY EMERGING TECHNOLOGIES
  • 6.1.1 DIELECTRIC BARRIER DISCHARGE (DBD)
  • 6.1.2 ATMOSPHERIC PRESSURE PLASMA JET (APPJ)
  • 6.1.3 PLASMA-ACTIVATED WATER/LIQUID (PAW/PAL)
• 6.2 COMPLEMENTARY TECHNOLOGIES
  • 6.2.1 ULTRAVIOLET LIGHT
  • 6.2.2 HYDROGEN PEROXIDE-BASED STERILIZATION
  • 6.2.3 LASER TECHNOLOGY
• 6.3 ADJACENT TECHNOLOGIES
  • 6.3.1 NANOTECHNOLOGY AND ANTIMICROBIAL COATINGS
  • 6.3.2 ADVANCED SURFACE TREATMENT TECHNOLOGIES
• 6.4 TECHNOLOGY/PRODUCT ROADMAP
  • 6.4.1 NEAR-TERM (2025-2027) INCLUDES ALL INDUSTRIES
  • 6.4.2 MID-TERM (2028-2030)
  • 6.4.3 LONG-TERM (2030+)
• 6.5 PATENT ANALYSIS
  • 6.5.1 JURISDICTION & TOP APPLICANT ANALYSIS
• 6.6 FUTURE APPLICATIONS
  • 6.6.1 PLASMA-ASSISTED PHARMACEUTICAL AND DRUG DELIVERY APPLICATIONS
  • 6.6.2 ADVANCED AGRICULTURAL AND PLANT-PRODUCTION APPLICATIONS
  • 6.6.3 FOOD WASTE VALORIZATION AND VALUE-ADDED FOOD PROCESSING
  • 6.6.4 ADVANCED CONTAMINANT REMEDIATION IN WATER AND WASTEWATER
  • 6.6.5 PLASMA-FUNCTIONALIZED BIOMATERIALS AND ADVANCED THERAPEUTIC MATERIALS
• 6.7 IMPACT OF AI/GENERATIVE AI ON COLD PLASMA MARKET
  • 6.7.1 TOP USE CASES AND MARKET POTENTIAL
  • 6.7.2 BEST PRACTICES
  • 6.7.3 CASE STUDIES OF AI IMPLEMENTATION
  • 6.7.4 INTERCONNECTED ADJACENT ECOSYSTEMS AND IMPACT ON MARKET PLAYERS
  • 6.7.5 CLIENTS' READINESS TO ADOPT GENERATIVE AI IN COLD PLASMA MARKET

7 REGULATORY LANDSCAPE AND SUSTAINABILITY INITIATIVES

• 7.1 REGIONAL REGULATIONS & COMPLIANCE
  • 7.1.1 NORTH AMERICA
  • 7.1.2 EUROPE
  • 7.1.3 ASIA PACIFIC
  • 7.1.4 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 7.1.5 INDUSTRY STANDARDS
    • 7.1.5.1 Medical Electrical Equipment Safety Standard - IEC 60601-1
    • 7.1.5.2 Non-thermal Plasma Wound-treatment Equipment Standard - IEC 60601-2-91:2026
    • 7.1.5.3 Quality Management System Standard For Medical Devices- ISO 13485:2016
    • 7.1.5.4 Cold Atmospheric Pressure Plasma Characterization Specification - DIN SPEC 91315:2025-07
    • 7.1.5.5 Environmental Management System Standard - ISO 14001:2026
    • 7.1.5.6 Quality Management System Standard - ISO 9001:2015
• 7.2 SUSTAINABILITY INITIATIVES
  • 7.2.1 SUSTAINABLE SURFACE TREATMENT THROUGH ATMOSPHERIC PLASMA - PLASMATREAT GMBH
  • 7.2.2 REDUCING VOLATILE ORGANIC COMPOUND (VOCS) AND CHEMICAL USE THROUGH ATMOSPHERIC PLASMA - MYCRONIC
• 7.3 IMPACT OF REGULATORY POLICIES ON SUSTAINABILITY INITIATIVES
  • 7.3.1 CERTIFICATIONS, LABELING, AND ECO-STANDARDS

8 CUSTOMER LANDSCAPE AND BUYER BEHAVIOR

• 8.1 DECISION-MAKING PROCESS
  • 8.1.1 DECISION-MAKING PROCESS
• 8.2 KEY STAKEHOLDERS & BUYING CRITERIA
  • 8.2.1 BUYING CRITERIA
• 8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES
• 8.4 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES
• 8.5 MARKET PROFITABILITY

9 COLD PLASMA MARKET, BY INDUSTRY

• 9.1 INTRODUCTION
• 9.2 POLYMER & PLASTIC INDUSTRY
  • 9.2.1 GROWING ADOPTION OF ECO-FRIENDLY SURFACE MODIFICATION TECHNOLOGIES
• 9.3 TEXTILE INDUSTRY
  • 9.3.1 COLD PLASMA TECHNOLOGY OFFERS COST-SAVING AND ECO-FRIENDLY OPTIONS FOR TEXTILE PROCESSING
• 9.4 ELECTRONICS & SEMICONDUCTOR INDUSTRY
  • 9.4.1 GROWING SEMICONDUCTOR INDUSTRY DEMANDS SUPPORT ADOPTION OF ADVANCED PLASMA PROCESSING TECHNOLOGIES
• 9.5 FOOD & AGRICULTURE INDUSTRY
  • 9.5.1 GROWING ADOPTION OF NON-THERMAL TECHNOLOGIES FOR FOOD PROCESSING AND AGRICULTURAL APPLICATIONS
• 9.6 MEDICAL INDUSTRY
  • 9.6.1 GROWING CLINICAL ADOPTION OF COLD PLASMA FOR WOUND HEALING AND ANTIMICROBIAL APPLICATIONS
• 9.7 COSMETICS INDUSTRY
  • 9.7.1 EXPANDING APPLICATION OF COLD PLASMA IN DERMATOLOGICAL AND AESTHETIC TREATMENTS
• 9.8 PHARMACEUTICAL INDUSTRY
  • 9.8.1 EXPANDING APPLICATION OF COLD PLASMA IN PHARMACEUTICAL STERILIZATION AND DRUG DELIVERY
• 9.9 OTHER INDUSTRIES

10 COLD PLASMA MARKET, BY APPLICATION

• 10.1 INTRODUCTION
• 10.2 SURFACE TREATMENT & ACTIVATION
  • 10.2.1 INCREASING DEMAND FOR IMPROVED SURFACE ADHESION AND ACTIVATION IN POLYMER PROCESSING
• 10.3 COATING & THIN-FILM DEPOSITION
  • 10.3.1 INCREASING APPLICATION OF COLD PLASMA FOR FUNCTIONAL AND PROTECTIVE SURFACE COATINGS
• 10.4 PRINTING
  • 10.4.1 BETTER DYE UPTAKE & PRINTING PERFORMANCE AND REDUCED RELIANCE ON WATER/CHEMICAL PRETREATMENT DRIVES ADOPTION
• 10.5 STERILIZATION & DECONTAMINATION
  • 10.5.1 INCREASING APPLICATION OF COLD PLASMA FOR STERILIZATION & DECONTAMINATION DRIVES MARKET
• 10.6 WOUND HEALING
  • 10.6.1 RISING PREVALENCE OF CHRONIC WOUNDS SUPPORTS USAGE OF COLD PLASMA IN WOUND MANAGEMENT
• 10.7 SURFACE ETCHING
  • 10.7.1 INCREASING REQUIREMENT FOR HIGH-PRECISION PLASMA ETCHING IN SEMICONDUCTOR MANUFACTURING
• 10.8 SURGICAL APPLICATIONS
  • 10.8.1 EXPANDING APPLICATIONS OF COLD PLASMA IN SURGICAL PROCEDURES AND CANCER TREATMENT
• 10.9 AESTHETIC SKIN PROCEDURES
  • 10.9.1 INCREASING DEMAND FOR NON-SURGICAL AESTHETIC PROCEDURES SUPPORTS COLD PLASMA APPLICATIONS
• 10.10 OTHER APPLICATIONS

11 COLD PLASMA MARKET, BY REGIME

• 11.1 INTRODUCTION
• 11.2 ATMOSPHERIC COLD PLASMA
  • 11.2.1 INCREASING ADOPTION OF ATMOSPHERIC COLD PLASMA FOR SCALABLE AND EFFICIENT SURFACE TREATMENT
• 11.3 LOW-PRESSURE COLD PLASMA
  • 11.3.1 HIGH TREATMENT EFFECTIVENESS SUPPORTS APPLICATIONS DESPITE VACUUM-SYSTEM LIMITATIONS

12 COLD PLASMA MARKET, BY REGION

• 12.1 INTRODUCTION
• 12.2 NORTH AMERICA
  • 12.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
  • 12.2.2 US
    • 12.2.2.1 Strong semiconductor investment, food-safety requirements, and medical applications support market growth
  • 12.2.3 CANADA
    • 12.2.3.1 Rising cancer cases & R&D to drive market growth in Canada
• 12.3 EUROPE
  • 12.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
  • 12.3.2 GERMANY
    • 12.3.2.1 Strong industrial base and demand for sustainable processing technologies propel adoption
  • 12.3.3 FRANCE
    • 12.3.3.1 Strong electronics and semiconductor investments support cold plasma market growth
  • 12.3.4 UK
    • 12.3.4.1 Investments in semiconductor and agricultural technologies support cold plasma adoption
  • 12.3.5 ITALY
    • 12.3.5.1 Aging population and healthcare investment support cold plasma market growth
  • 12.3.6 SPAIN
    • 12.3.6.1 Growing healthcare needs and cancer burden support cold plasma applications in Spain
  • 12.3.7 REST OF EUROPE
• 12.4 ASIA PACIFIC
  • 12.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
  • 12.4.2 CHINA
    • 12.4.2.1 Strong textile, electronics, and food-processing industries support cold plasma adoption in China
  • 12.4.3 JAPAN
    • 12.4.3.1 Aging population, healthcare needs, and advanced manufacturing support cold plasma applications in Japan
  • 12.4.4 INDIA
    • 12.4.4.1 Growing R&D investment and textile exports support cold plasma adoption in India
  • 12.4.5 AUSTRALIA
    • 12.4.5.1 Growing healthcare needs and medical R&D support cold plasma adoption in Australia
  • 12.4.6 SOUTH KOREA
    • 12.4.6.1 Government support and advanced healthcare infrastructure support cold plasma adoption in South Korea
  • 12.4.7 REST OF ASIA PACIFIC
• 12.5 LATIN AMERICA
  • 12.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
  • 12.5.2 BRAZIL
    • 12.5.2.1 Growing R&D investment and healthcare innovation support cold plasma adoption in Brazil
  • 12.5.3 MEXICO
    • 12.5.3.1 Growing healthcare needs support cold plasma adoption in Mexico
  • 12.5.4 REST OF LATIN AMERICA
• 12.6 MIDDLE EAST & AFRICA
  • 12.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
  • 12.6.2 GCC COUNTRIES
    • 12.6.2.1 Kingdom of Saudi Arabia
      • 12.6.2.1.1 Healthcare modernization and technology development drive cold plasma adoption in Saudi Arabia
    • 12.6.2.2 UAE
      • 12.6.2.2.1 Healthcare innovation and advanced technology development support cold plasma adoption in the UAE
    • 12.6.2.3 Rest of GCC Countries
  • 12.6.3 REST OF MIDDLE EAST & AFRICA

13 COMPETITIVE LANDSCAPE

• 13.1 INTRODUCTION
• 13.2 KEY PLAYER STRATEGIES/RIGHT TO WIN, 2023-2026
  • 13.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN COLD PLASMA MARKET
• 13.3 REVENUE ANALYSIS, 2023-2025
• 13.4 MARKET SHARE ANALYSIS, 2025
  • 13.4.1 GLOBAL SHARE ANALYSIS FOR COLD PLASMA MARKET (2025)
  • 13.4.2 US MARKET SHARE ANALYSIS FOR COLD PLASMA MARKET (2025)
  • 13.4.3 EUROPE MARKET SHARE ANALYSIS FOR COLD PLASMA MARKET (2025)
• 13.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025
  • 13.5.1 STARS
  • 13.5.2 EMERGING LEADERS
  • 13.5.3 PERVASIVE PLAYERS
  • 13.5.4 PARTICIPANTS
  • 13.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025
    • 13.5.5.1 Company footprint
    • 13.5.5.2 Region footprint
    • 13.5.5.3 Industry footprint
    • 13.5.5.4 Application footprint
    • 13.5.5.5 Regime footprint
• 13.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
  • 13.6.1 PROGRESSIVE COMPANIES
  • 13.6.2 RESPONSIVE COMPANIES
  • 13.6.3 DYNAMIC COMPANIES
  • 13.6.4 STARTING BLOCKS
  • 13.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025
    • 13.6.5.1 Detailed list of key startups/SMEs
    • 13.6.5.2 Competitive benchmarking of key startups/SMEs
• 13.7 COMPANY VALUATION AND FINANCIAL METRICS
  • 13.7.1 FINANCIAL METRICS
  • 13.7.2 COMPANY VALUATION
• 13.8 BRAND/PRODUCT COMPARISON
• 13.9 COMPETITIVE SCENARIO
  • 13.9.1 PRODUCT LAUNCHES & APPROVALS
  • 13.9.2 DEALS
  • 13.9.3 EXPANSIONS
  • 13.9.4 OTHER DEVELOPMENTS

14 COMPANY PROFILES

• 14.1 KEY PLAYERS
  • 14.1.1 NORDSON CORPORATION
    • 14.1.1.1 Business overview
    • 14.1.1.2 Products offered
    • 14.1.1.3 Recent developments
      • 14.1.1.3.1 Deals
      • 14.1.1.3.2 Expansions
      • 14.1.1.3.3 Other developments
    • 14.1.1.4 MnM view
      • 14.1.1.4.1 Right to win
      • 14.1.1.4.2 Strategic choices
      • 14.1.1.4.3 Weaknesses & competitive threats
  • 14.1.2 ADTEC PLASMA TECHNOLOGY CO., LTD.
    • 14.1.2.1 Business overview
    • 14.1.2.2 Products offered
    • 14.1.2.3 Recent developments
      • 14.1.2.3.1 Product launches
      • 14.1.2.3.2 Deals
      • 14.1.2.3.3 Expansions
      • 14.1.2.3.4 Other developments
    • 14.1.2.4 MnM view
      • 14.1.2.4.1 Right to win
      • 14.1.2.4.2 Strategic choices
      • 14.1.2.4.3 Weaknesses and competitive threats
  • 14.1.3 JUDGES SCIENTIFIC PLC
    • 14.1.3.1 Business overview
    • 14.1.3.2 Products offered
    • 14.1.3.3 Recent developments
      • 14.1.3.3.1 Product launches & updates
      • 14.1.3.3.2 Deals
    • 14.1.3.4 MnM view
      • 14.1.3.4.1 Right to win
      • 14.1.3.4.2 Strategic choices
      • 14.1.3.4.3 Weaknesses and competitive threats
  • 14.1.4 PVA TEPLA AG
    • 14.1.4.1 Business overview
    • 14.1.4.2 Products offered
    • 14.1.4.3 MnM view
      • 14.1.4.3.1 Right to win
      • 14.1.4.3.2 Strategic choices
      • 14.1.4.3.3 Weaknesses and competitive threats
  • 14.1.5 BODYCOTE
    • 14.1.5.1 Business overview
    • 14.1.5.2 Products offered
    • 14.1.5.3 Recent developments
      • 14.1.5.3.1 Other developments
    • 14.1.5.4 MnM view
      • 14.1.5.4.1 Right to win
      • 14.1.5.4.2 Strategic choices
      • 14.1.5.4.3 Weaknesses and competitive threats
  • 14.1.6 APYX MEDICAL CORPORATION
    • 14.1.6.1 Business overview
    • 14.1.6.2 Products offered
    • 14.1.6.3 Recent developments
      • 14.1.6.3.1 Product launches & approvals
      • 14.1.6.3.2 Other developments
  • 14.1.7 VIROMED MEDICAL AG
    • 14.1.7.1 Business overview
    • 14.1.7.2 Products offered
    • 14.1.7.3 Recent developments
      • 14.1.7.3.1 Product approvals
      • 14.1.7.3.2 Deals
      • 14.1.7.3.3 Other developments
  • 14.1.8 SAMCO INC.
    • 14.1.8.1 Business overview
    • 14.1.8.2 Products offered
    • 14.1.8.3 Recent developments
      • 14.1.8.3.1 Product launches
  • 14.1.9 MYCRONIC
    • 14.1.9.1 Business overview
    • 14.1.9.2 Products offered
    • 14.1.9.3 Recent developments
      • 14.1.9.3.1 Deals
      • 14.1.9.3.2 Other developments
  • 14.1.10 PLASMATREAT GMBH
    • 14.1.10.1 Business overview
    • 14.1.10.2 Products offered
    • 14.1.10.3 Recent developments
      • 14.1.10.3.1 Product launches
      • 14.1.10.3.2 Deals
      • 14.1.10.3.3 Expansions
      • 14.1.10.3.4 Other developments
  • 14.1.11 P2I LTD
    • 14.1.11.1 Business overview
    • 14.1.11.2 Products offered
    • 14.1.11.3 Recent developments
      • 14.1.11.3.1 Deals
      • 14.1.11.3.2 Other developments
  • 14.1.12 ENERCON INDUSTRIES CORPORATION
    • 14.1.12.1 Business overview
    • 14.1.12.2 Products offered
    • 14.1.12.3 Recent developments
      • 14.1.12.3.1 Product launches
      • 14.1.12.3.2 Expansions
  • 14.1.13 TANTEC A/S
    • 14.1.13.1 Business overview
    • 14.1.13.2 Products offered
    • 14.1.13.3 Recent developments
      • 14.1.13.3.1 Product launches
      • 14.1.13.3.2 Deals
  • 14.1.14 ACXYS TECHNOLOGIES
    • 14.1.14.1 Business overview
    • 14.1.14.2 Products offered
    • 14.1.14.3 Recent developments
      • 14.1.14.3.1 Product launches
  • 14.1.15 KEYLINK
    • 14.1.15.1 Business overview
    • 14.1.15.2 Products offered
    • 14.1.15.3 Recent developments
      • 14.1.15.3.1 Other developments
• 14.2 OTHER PLAYERS
  • 14.2.1 DIENER ELECTRONIC GMBH & CO.KG
  • 14.2.2 US MEDICAL INNOVATIONS
  • 14.2.3 LEAFLIFE TECHNOLOGY
  • 14.2.4 SOFTAL CORONA & PLASMA GMBH
  • 14.2.5 FERRARINI & BENELLI SRL
  • 14.2.6 NEOPLAS MED GMBH
  • 14.2.7 TERRAPLASMA GMBH
  • 14.2.8 MOLECULAR PLASMA GROUP
  • 14.2.9 CINOGY TECHNOLOGIES GMBH
  • 14.2.10 PLASMALEX

15 RESEARCH METHODOLOGY

• 15.1 RESEARCH DATA
  • 15.1.1 SECONDARY DATA
    • 15.1.1.1 Key data from secondary sources
  • 15.1.2 PRIMARY DATA
    • 15.1.2.1 Key data from primary sources
    • 15.1.2.2 Key industry insights
    • 15.1.2.3 Breakdown of primary interviews
    • 15.1.2.4 Key industry insights
• 15.2 MARKET SIZE ESTIMATION
  • 15.2.1 APPROACH 1: COMPANY REVENUE ANALYSIS APPROACH
  • 15.2.2 APPROACH 2: CUSTOMER-BASED MARKET ESTIMATION
  • 15.2.3 BOTTOM-UP APPROACH: SUPPLY-SIDE ANALYSIS
  • 15.2.4 TOP-DOWN APPROACH
  • 15.2.5 BASE NUMBER CALCULATION
  • 15.2.6 DEMAND-SIDE APPROACH
• 15.3 MARKET BREAKDOWN AND DATA TRIANGULATION
• 15.4 MARKET SHARE ASSESSMENT
• 15.5 RESEARCH ASSUMPTIONS
  • 15.5.1 STUDY ASSUMPTIONS
  • 15.5.2 GROWTH RATE ASSUMPTIONS
• 15.6 RISK ASSESSMENT
• 15.7 RESEARCH LIMITATIONS

16 APPENDIX

• 16.1 DISCUSSION GUIDE
• 16.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 16.3 CUSTOMIZATION OPTIONS
  • 16.3.1 PRODUCT ANALYSIS
  • 16.3.2 GEOGRAPHIC ANALYSIS
• 16.4 RELATED REPORTS
• 16.5 AUTHOR DETAILS